×

Innocoll to Report First Quarter 2016 Financial Results and Host Webcast and Conference Call on May 31, 2016

ATHLONE, Ireland, May 18, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that it will report first quarter financial results after the close of U.S. financial markets on May 31, 2016. Innocoll management will host a webcast and conference call at 4:30 p.m. EDT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-407-4018 for domestic callers and 201-689-8471 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at www.innocoll.com and will be archived there for 90 days. A telephone replay of the call will be available until 11:59 p.m. EDT on June 3, 2016 by dialing 877-870-5176 for domestic callers or 858-384-5517 for international callers and entering the conference code: 13637980.

About Innocoll Holdings PLC

Innocoll is a global, commercial-stage, specialty pharmaceutical company that is dedicated to engineering better medicines to help patients get better. Our proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use. Applied locally to wound and/or surgery sites, they are designed to provide a range of benefits. The company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColL for the treatment of postoperative pain; INL-002, a gentamicin-collagen topical matrix for the adjuvant treatment of diabetic foot infections; and INL-003, a barrier for the prevention of post-surgical adhesions.

Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®, some of which are sold globally through strategic partnerships, including those with Takeda, EUSA Pharma, Biomet 3i and Biomet. All of our native collagen products—from extraction/purification of type-1 collagen through final delivery form—are manufactured at our certified, integrated plant in Saal, Germany.

For more information, please visit www.innocoll.com.

CollaRx®, Collatamp®, COLLAGUARD®, Collieva®, CollaCare®, Collexa®, COGENZIA® LidoColl®, LiquiColl®, and XARACOLL® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the company.

Contact: Pepe Carmona Chief Financial Officer (215) 983-3362 pcarmona@innocollinc.com Jeannie Sorenson, M.D. Vice President, Investor Relations (314) 458-7355 jsorenson@innocoll.com

Source:Innocoll Holdings plc